Soluble Epoxide Hydrolase Inhibition and Insulin Resistance

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

November 18, 2021

Study Completion Date

November 18, 2021

Conditions
Diabetes MellitusEndocrine System DiseasesGlucose Metabolism DisordersPreDiabetesObesity
Interventions
DRUG

GSK2256294

Drug will be taken daily by mouth for 7 days.

DRUG

Placebo oral capsule

Placebo will be taken daily by mouth for 7 days.

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Vanderbilt University Medical Center

OTHER

NCT03486223 - Soluble Epoxide Hydrolase Inhibition and Insulin Resistance | Biotech Hunter | Biotech Hunter